Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys, La Jolla, California.
Clin Cancer Res. 2020 Jan 1;26(1):3-5. doi: 10.1158/1078-0432.CCR-19-3119. Epub 2019 Nov 5.
CDK4/6 inhibitors have emerged as a significant advance for the treatment of patients with advanced estrogen receptor-positive breast cancer. However, the identification of predictive markers that optimize their use is proving harder than expected. In this commentary we advocate for unbiased discovery and a collaborative approach across trials..
CDK4/6 抑制剂的出现是晚期雌激素受体阳性乳腺癌治疗的重大进展。然而，鉴定能优化其使用的预测标志物比预期的更具挑战性。在这篇评论中，我们提倡在试验中进行无偏见的发现和协作。
